IOIrvin Oh

Irvin Oh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Irvin Oh has a total of 207 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models

    by Wenyu Fu, Ronghan Liu, Jin Wo, Xin Liu, Shuya Wang, Wenhao Song, Haoran Zhu, Yazhou Cui, Yuehong Chen, Chao Wang, et al.

    Osteoarthritis (OA), a leading cause of disability, is characterized by chronic low-grade inflammation and metabolic dysregulation in chondrocytes. TNF-α and IL-1β are key inflammatory drivers in OA pathogenesis, but clinical trials targeting them individually have been unsuccessful, highlighting the potential need for dual-targeting strategies. By screening a US Food and Drug Administration–approved drug library, we identified dabigatran, a thrombin inhibitor, as a potent dual suppressor of TNF-α and IL-1β signaling that restored chondrocyte metabolism. In preclinical OA models, including both mice and cynomolgus macaques, dabigatran attenuated cartilage degeneration, alleviated pain, and improved joint function. To elucidate the molecular mechanisms, we performed biochemical copurification coupled with mass spectrometry, identifying brefeldin A–inhibited guanine nucleotide–exchange protein 2 (BIG2) as a previously unknown dabigatran-binding target. Mechanistically, dabigatran binds to BIG2, promoting BIG2-dependent TNFR1 release to dampen TNF-α signaling while enhancing BIG2-mediated IL-1R1 degradation through the autophagy-lysosome pathway to limit IL-1β effects. These findings establish BIG2-mediated receptor trafficking and membrane dynamics as a regulatory node that concurrently inhibits TNF-α and IL-1β signaling, suggesting this pathway as a potential therapeutic strategy for OA.

  • Open Access

    Accuracy and Consistency of a Patient-Specific 3D-Printed Guide in Minimally Invasive Medializing Calcaneal Osteotomy: A Controlled Cadaveric Study

    by Isabella Paoletti, Aiden Reuter, Jiyoun Kim, Clotilde Roesch, Alyssa Glennon, Irvin Oh

    Background: Minimally invasive medializing calcaneal osteotomy (MCO) is used to correct hindfoot valgus deformity. However, limited visualization may introduce variability in osteotomy trajectory and medial translation, affecting the accuracy and reproducibility of deformity correction. Patient-specific 3D-printed guides (PSGs) may improve precision, but their stability and accuracy remain unestablished. This study evaluated an externally applied PSG for minimally invasive MCO in a controlled cadaveric model. Methods: Ten formaldehyde-embalmed foot and ankle specimens were studied. Computed tomography–based PSGs were designed for each specimen. The primary outcome was absolute translational error for a planned 6-mm medial displacement comparing PSG-guided with freehand MIS MCO. Secondary outcomes were guide stability, planned-vs-achieved osteotomy agreement, and PSG-guided translation consistency across 6-, 8-, and 10-mm targets. The freehand control used no fluoroscopy and represented an experimental comparator. Agreement was assessed using linear regression and Bland-Altman analysis. Results: With the numbers available, no statistically significant relationship was detected between pin number and angular deviation ( r = −0.13, P = .47). PSG-guided MCO demonstrated lower absolute translational error than the freehand comparator (0.38 ± 0.42 mm vs 2.51 ± 1.82 mm; mean paired difference 2.13 mm, 95% CI 1.07-3.19; P = .001). With the numbers available, no statistically significant effect of insert size on signed translational error was detected ( P = .675). Planned and achieved osteotomy position demonstrated a mean absolute deviation of 0.74 ± 0.31 mm (95% CI 0.55-0.93) and strong correlation ( R 2 = 0.969). These results demonstrate technical feasibility and accuracy in a small cadaveric model and do not establish clinical superiority. Conclusion: In this controlled cadaveric proof-of-concept study, externally applied PSG-assisted MIS MCO demonstrated lower translational error than a nonfluoroscopic freehand comparator and reproduced the preoperative plan with submillimeter mean absolute deviation. Clinical relevance remains unknown; further studies are needed to determine whether these technical improvements translate to improved patient outcomes. Level of Evidence: Level V, cadaveric study.

  • Open Access

    Synthetic short peptide mimicking IsdB and IsdH conserved motifs selectively bind and enable detection of Staphylococcus aureus infection

    by Taiwo Samuel Samuel Agidigbi, Irvin Oh

    Background: Staphylococcus aureus ( S. aureus ) is the most common pathogen in musculoskeletal infections (MSKI). Application of antibody responses to S. aureus virulence factors have suggested to improve diagnostic specificity. Iron acquisition plays a crucial role in S. aureus pathogenesis. The bacterium scavenges iron from the host by expressing cell surface receptors that bind heme and hemoglobin through the iron-regulated surface determinant (Isd) system. These heme and hemoglobin binding motifs are essential for bacterial survival and virulence. In particular, the highly conserved region of the near iron transport (NEAT) domain may serve as a target for diagnostic applications. Methods: Based on our review of multiple IsdB and IsdH amino acids sequences, we identified a highly conserved near iron transport (NEAT) domains that are unique to S. aureus . We designed and synthesized two short peptides: IsdB-NEAT2, containing the heme binding motifs, and IsdH-NEAT2, containing the hemoglobin binding motif. Each represents the most highly conserved region of the IsdB and IsdH. We utilized infected tissue culture and Staphylococcal complement inhibitor (SCIN) as an adjunct reference. We used enzyme-linked immunosorbent assay (ELISA) with three antigens; IsdB-NEAT2, IsdH-NEAT2, and SCIN to measure reactivity of sera from three groups: patients with S. aureus MSKI (N = 20), patients with MSKI due to other microbial etiologies (N = 20), and healthy controls (N = 21). Circulating immunoglobulins IgM and IgG were measured. Cytokines production by peripheral blood mononuclear cells (PBMC) following stimulation with IsdB-NEAT 2 and IsdH-NEAT 2 antigens were comparatively analyzed against PBMCs from a control group not challenged with S. aureus -specific antigens. Results: Sera from S. aureus -infected patients showed significantly elevated ELISA optical density (OD) reactivity with IsdB-N2, IsdH-N2, and SCIN (p 0.99) respectively compared to healthy controls. Comparisons with other MSKI, sera from S. aureus -associated MSKI yielded significant differences for all three antigens IsdB-N2, IsdH-N2, and SCIN (p S. aureus patients vs. healthy controls (both p = 0.0001). Antigen-specific IgM and IgG levels were significantly elevated in the S. aureus group vs. healthy controls for all three antigens (IgM: IsdB-N2, p = 0.0057; IsdH-N2, p = 0.0040; SCIN, p = 0.0011; IgG: IsdB-N2, p = 0.0499; IsdH-N2, p = 0.0207; SCIN, p = 0.0068). Both peptides stimulated significant cytokine production by PBMCs compared with the untreated PBMCs, inducing IL-6, IL-8, IL-10, IL-1β, MCP-1, TNF-α, EGF , and RANTES . Conclusions: Our findings indicate that humoral responses to the novel S. aureus antigens (IsdB-NEAT2, IsdH-NEAT2) were able to differentiate S. aureus associated MSKI from other infections, and from healthy controls. Both IsdB-NEAT2 and IsdH-NEAT2 stimulated pro-inflammatory and chemotactic cytokines, confirming that these short-sequenced antigenic motifs activated the innate immune system. This study presents a novel, shortened, and highly conserved component of synthetic Isd peptides, that mimics the functional heme and hemoglobin binding motifs of S. aureus Isd proteins, which could be utilized for diagnosis of S. aureus MSKI.

  • Open Access

    Medial Gastrocnemius Recession

    by Irvin Oh, Jeremy Ansah-Twum, Arianna Gianakos, Kinjal Vasavada

  • CD177, MYBL2, and RRM2 Are Potential Biomarkers for Musculoskeletal Infections

    by Taiwo Samuel Agidigbi, Brianna Fram, Ilda Molloy, Matthew Riedel, Daniel Wiznia, Irvin Oh

    Background: Biomarkers of infection are measurable indicators that reflect the presence of an infection in the body. They are particularly valuable for detecting infections and tracking treatment responses. Previous transcriptome analysis of peripheral blood mononuclear cells (PBMCs) collected from patients during the active phase of diabetic foot infection identified the upregulation of several genes, including a neutrophil-specific cell surface glycoprotein, CD177, an Myb-related transcription factor 2 (MYBL2), and ribonucleotide reductase regulatory subunit M2 (RRM2). We aimed to investigate whether these observations in diabetic foot infections could be extrapolated to other musculoskeletal infections. Questions/purposes: (1) Are the protein concentrations of CD177, MYBL2, and RRM2 elevated in serum or PBMCs of patients with musculoskeletal infections? (2) Do serum and PBMC concentrations of CD177, MYBL2, and RRM2 decrease in response to antibiotic therapy? (3) Can these biomarkers give diagnostic accuracy and differentiate patients with musculoskeletal infections from controls? Methods: From April 2023 to June 2024, we treated 26 patients presenting with clinical symptoms and signs of acute musculoskeletal infections, including elevated inflammatory markers (white blood cell [WBC] and C-reactive protein [CRP]) and local changes such as swelling, erythema, tenderness or pain, warmth, purulent drainage, sinus tract, or wound leading to bone or hardware. Diagnosis included periprosthetic joint infection (PJI), foot and ankle infection (FAI), fracture-related infection (FRI), and septic arthritis of the native joints. Patients with chronic recurrent osteomyelitis, PJI, or FRI were excluded from the study. Among the 26 patients deemed potentially eligible, 19% (5) were excluded for the following reasons: prison inmate (1), unable to provide consent because of severe sepsis (1), mental illness (1), and declined to participate (2). Of the 81% (21) of patients who provided consent, cultures from 9.5% (2) were negative. These two patients were ultimately diagnosed with inflammatory arthritis: gout (1) and rheumatoid arthritis (1); thus, the musculoskeletal infection group for analysis consisted of 73.1% (19 of 26) of patients. A control group of 21 patients undergoing elective foot or ankle deformity correction surgery without infections or systemic inflammation was included. Because foot or ankle deformity is highly unlikely to influence the immunologic profile of the subjects, we believed that these patients would serve as an appropriate control group. Other than the absence of infection and the lower prevalence of diabetes mellitus, the control group was comparable to the study group in terms of demographics and clinical factors, including age and sex distribution. We collected blood samples from both patients and controls and quantified CD177, MYBL2, and RRM2 RNA transcription levels in the PBMC using qRT-PCR. We also assessed protein concentrations in the serum and PBMC using an enzyme-linked immunosorbent assay. A comparative analysis of the three biomarkers was performed on 19 patients with musculoskeletal infections with positive cultures and 21 controls to assess their diagnostic potential using the unpaired nonparametric t-test with the Mann-Whitney test. We obtained 8-week follow-up blood samples from seven patients with musculoskeletal infections who clinically healed. Healing was defined by normalization of inflammatory markers (WBC and CRP) and absence of swelling, erythema, local tenderness or pain, warmth, purulent drainage, sinus tract, or open wound. We performed a comparative analysis of the seven patients during active infection and after treatment to determine a change in the level of CD177, MYBL2, and RRM2 in their serum and PBMCs. These findings were also compared with those of the control group. We evaluated the diagnostic accuracy of CD177, MYBL2, and RRM2 for musculoskeletal infections using receiver operating characteristic (ROC) curve analysis. Results: The musculoskeletal infections group showed a larger increased serum and PBMC concentrations of CD177, MYBL2, and RRM2 proteins compared with the control group. The mean protein concentrations of CD177, MYBL2, and RRM2 were increased in the serum and PBMC of the musculoskeletal infections group compared with the controls. Serum levels of all biomarkers investigated were higher in musculoskeletal infections group compared with the control group (CD177 227 [155 to 432] versus 54 [10 to 100], difference of medians 173, p < 0.01; MYBL2 255 [231 to 314] versus 180 [148 to 214], difference of medians 75, p < 0.01; RRM2 250 [216 to 305] versus 190 [148 to 255], difference of medians 60, p < 0.01). Similarly, PBMC levels of all biomarkers were higher in the musculoskeletal infections group (CD177 55.3 [39.1 to 80.5] versus 17.5 [10.5 to 27.5], difference of medians 37.8, p < 0.01; MYBL2 144 [114 to 190] versus 91 [70 to 105], difference of medians 53, p < 0.01; RRM2 168 [143 to 202] versus 100 [77.5 to 133], difference of medians 68, p < 0.01). Additionally, serum levels of all biomarkers decreased in seven patients with musculoskeletal infections after infection treatment (CD177 3080 [2690 to 3320] versus 4250 [3100 to 8640], difference of medians 1170, p < 0.01; MYBL2 4340 [4120 to 4750] versus 5010 [4460 to 5880], difference of medians 670, p < 0.01; RRM2 4350 [3980 to 5000] versus 5025 [4430 to 6280], difference of medians 675, p = 0.01). Similarly, PBMC levels of all biomarkers were lower after infection treatment (CD177 805 [680 to 980] versus 1025 [750 to 1610], difference of medians 220, p < 0.01; MYBL2 2300 [2100 to 2550] versus 2680 [2220 to 3400], difference of medians 380, p = 0.02; RRM2 2720 [2500 to 3200] versus 3350 [2825 to 4030], difference of medians 630, p < 0.01). The area under the ROC curve for diagnosing musculoskeletal infections in the serum and PBMC was as follows: CD177 95% confidence interval [CI] > 0.99 and > 0.99, MYBL2 95% CI > 0.99 and > 0.99, and RRM2 95% CI = 0.96 and > 0.99, respectively. Conclusion: We may utilize blood-based tests for CD177, MYBL2, and RRM2 to aid in the diagnosis of musculoskeletal infections, particularly when arthrocentesis or obtaining tissue culture is challenging. They may also assist in monitoring treatment response. As some of these biomarkers may also be elevated in other inflammatory conditions, a large-scale clinical study is needed to confirm their reliability in differentiating musculoskeletal infections from other inflammatory conditions. Clinical Relevance: CD177, MYBL2, and RRM2 proteins in blood samples may serve as novel biomarkers for diagnosing and monitoring treatment response in musculoskeletal infections.


  • Open Access

    Clinical challenges and advancements in diagnosing Staphylococcus aureus-associated musculoskeletal infections

    by Irvin Oh

    Musculoskeletal infections (MSKI) present a significant health challenge, with a rising incidence linked to the aging population and advancements in orthopedic surgical care. Staphylococcus aureus is the most prevalent pathogen associated with orthopedic infections. The conventional culture method for identification of pathogen frequently lacks accuracy and is challenged by false-positive or false-negative results. Inflammatory markers such as the erythrocyte sedimentation rate and C-reactive protein are not site-specific or accurate, as they can be confounded by other medical conditions. Identifying the dominant pathogen and monitoring treatment response following surgical debridement and antibiotics therapy continues to pose challenges. Understanding the pathogenesis of MSKI is crucial for the development of innovative diagnostics and alternative therapeutics. S. aureus immune evasion stands out as a key component of the pathogenic mechanism, complicating clinical decisions. Other unique mechanisms such as biofilm and abscess formation, as well as osteocyte-lacuno canalicular network invasion, underscore the need for aggressive debridement and the complete removal of infected implants and bone tissues. Ongoing efforts focus on exploring and developing innovative diagnostics, such as serum immunoassays, next-generation sequencing of infected tissue, transcriptomics of peripheral blood mononuclear cells, and serum proteomics. These endeavors offer promising avenues for improved diagnostics, medical management, and innovative therapeutics for MSKI.

  • Biomechanical Effects of Subtalar Joint Fusion and Medial Ligament Reconstruction in Simulated Progressive Collapsing Foot Deformity

    by Wonyong Lee, Nahom Tecle, Emma Knapp, Hani Awad, Irvin Oh

    Background: The purpose of this study is to investigate the biomechanical effect of medial displacement calcaneal osteotomy (MDCO), subtalar joint fusion (SF), and medial ligament reconstruction (MLR: deltoid-spring ligament) in a severe flatfoot model. We hypothesized that (1) combination of MDCO and SF improves the tibiotalar and foot alignment in severe progressive collapsing foot deformity (PCFD) cadaver model. (2) However, if a residual valgus heel alignment remains after MCDO and SF, it can lead to increased medial ligament strain, foot malalignment, and tibiotalar valgus tilt, which will be mitigated by the addition of MLR. Methods: Ten fresh-frozen cadaveric foot specimens were used to create a severe flatfoot model. The foot alignment changes, including the talo–first metatarsal angle in the axial and sagittal planes, subtalar angle, and tibiotalar angle in the coronal plane, were measured. The angles were measured at the initial condition, after creating the severe flatfoot model, and after each successive reconstructive procedure in the following order: (1) MDCO, (2) SF, and (3) MLR. Results: Tibiotalar valgus tilt was decreased with the MDCO procedure: 4.4 vs 1.0 degrees ( P = .04). Adding in situ SF to the MDCO led to increased tibiotalar tilt to 2.5 degrees was different from the initial condition ( P = .01). Although the tibiotalar valgus tilt was significantly decreased after adding the MLR to the MDCO/SF procedure compared with the severe flatfoot model (0.8 vs 4.4 degrees, P = .03), no significant difference in the tibiotalar valgus tilt was observed between MDCO/SF and MDCO/SF with MLR. Conclusion: Our results demonstrated that MDCO significantly improved forefoot abduction and medial arch alignment, with no significant additional improvement observed with addition of SF. Following SF, a residual valgus heel alignment can contribute to subsequent tibiotalar valgus tilt. The addition of MLR did not show significantly decreased tibiotalar valgus tilt following SF. Clinical Relevance: Residual valgus heel alignment after subtalar joint fusion in the surgical treatment of PCFD can lead to increased medial ligament strain. Although MLR might be considered for providing medial stability, it may not necessarily prevent the development of tibiotalar valgus tilt.


  • Open Access

    The Burden of Revision Total Ankle Replacement Has Markedly Increased from 2010 to 2020

    by Philip P. Ratnasamy, Gwyneth Maloy, Oghenewoma Oghenesume, Sean C. Peden, Jonathan N. Grauer, Irvin Oh

    Category: Ankle Arthritis Introduction/Purpose: Total ankle replacement (TAR) surgery has steadily increased in recent decades. The aim of the current study was to investigate the evolving burden of revision surgery and risk factors and timing of revision or implant removal. We hypothesized that there has been an increase in revision TAR and explant surgeries in the past decade and that younger age and higher comorbidity burden are risk factors for revision and explant. Methods: Using the 2010-2020 PearlDiver M151Ortho dataset, this retrospective cohort study identified primary TAR, TAR revision, and TAR explant patients. This is a large national database containing billing claims information on over 151 million patients in the United States across all payer types and sites of care. Patient factors investigated included age, sex, and Elixhauser Comorbidity Index (ECI, a longitudinal measure of patient comorbidity burden generated using ICD-9 and ICD-10 diagnosis codes). Annual incidence for primary and revision TAR, and explant were recorded. Multivariate logistic regression analyses were performed to determine independent risk factors for revision TAR or explant relative to primary TAR. For explants, the eventual intervention by two years was analyzed. Ten-year timing and survival to revision or explant surgery following patient-matched unilateral TAR were characterized. Results: Over the study period, there were 10,531 primary, 1,218 revision, and 1,735 explant TARs (increasing by 310%, 398%, and 9.6%, respectively). Independent predictors of revision TAR included: younger age (odds ratio [OR] 1.29 per decade decrease) and higher ECI (OR 1.23 per 2-point increase) (p < 0.0001 for both). Independent predictors of explant surgery included: younger age (OR 1.80 per decade decrease, p< 0.0001), female sex (OR 1.17, p=0.0011), and higher ECI (OR 1.35 per 2-point increase, p< 0.0001). Explanted patients went on to arthrodesis (37.7%), amputation (26.1%), revision TAR (14.7%), or no identified procedure/other procedures (21.5%) within the subsequent two years. The 10-year implant survival rate following primary TAR was 91.8%. 73% and 83% of revisions and explants occurred in the first three years following index TAR, respectively. Conclusion: The burden of TAR revision has grown substantially over the past decade. Younger age, female sex, and higher patient comorbidity burden were associated with increased risk of revision or explant surgery. If explant is pursued, most went on to arthrodesis or amputation. These results suggest that care should be taken in patient selection for TAR to minimize the occurrence of revision and explant surgery. Treatment algorithms should be modified to optimize outcomes among patients who undergo explant or revision surgery.

  • Open Access

    Utilization of PROMIS Neuropathic Pain Quality for Detection and Monitoring Neuropathic Pain in Heel Pain Patients

    by Peter Y. Joo, Wonyong Lee, Samantha Hoffman, Judith Baumhauer, Irvin Oh

    Background: Diagnosis and management of neuropathic pain (NP) in foot and ankle patients remain challenging. We investigated the plausibility of using Patient-Reported Outcomes Measurement Information System (PROMIS) Neuropathic Pain Quality (PQ-Neuro) as an initial screening tool to detect NP and track the treatment effects. Methods: Patients with heel pain were prospectively recruited and grouped to no-NP, mild-NP, and severe-NP based on the initial PROMIS PQ-Neuro t scores. Pain Interference (PI), Physical Function (PF), and Self-Efficacy (SE) scores were evaluated at baseline, 30-day, and 90-day follow-up. Other factors such as age, smoking, body mass index (BMI), low back/neck pain, anxiety/depression, and medications were analyzed. Linear mixed modeling was used to assess the main effects of time and NP on PROMIS t scores, comparing minimal clinically important difference (MCID). Results: Forty-eight patients with mean age of 52.4 years were recruited. Using the PROMIS PQ-Neuro as the assessment tool, 33 patients (69%) were detected to have NP at baseline—23 (48%) mild and 10 (21%) severe. BMI was the only independent factor associated with NP ( P = .011). Higher baseline PQ-Neuro t score was significantly associated with higher follow-up PQ-Neuro ( P < .001), PI ( P = .005), and lower SE ( P = .04) across time points. Patients with NP showed lower PF at baseline with significantly less improvement in PF (3 vs 9.9, P = .035) and did not meet MCID. Conclusion: Baseline PROMIS PQ-Neuro ≥46 was significantly associated with worse PI and SE across all time points, with less clinically significant improvements in PF. Prevalence of NP in heel pain patients was high. The PROMIS PQ-Neuro may serve as a valuable tool for detection of NP and guiding clinical treatment decision pathways for heel pain patients. Level of Evidence: Level III, prospective cohort study.


  • Clinical presentation of group B Streptococcus-infected diabetic foot ulcers

    by Olivia V Waldman, Brandon J Dexter, Aron Sulovari, Irvin C Oh

    Objective: Group B Streptococcus (GBS) is a common pathogen in diabetic foot ulcers (DFUs), where it has been found to result in higher rates of soft tissue infection and amputation despite appropriate treatment. In this study, we aim to investigate clinical characteristics and prognosis of GBS DFU infections, especially those with tenosynovial involvement. We hypothesise that GBS-infected DFUs with tenosynovial involvement leads to an increased number of recurrent infections and unexpected returns to the operating room. Method: Data were retrospectively collected from GBS-infected DFU patients surgically treated by an orthopaedic foot and ankle surgeon over a four-year period. Demographics, comorbidities, initial laboratory values and culture results from infected bone samples were recorded. Clinical outcome was assessed by recurrent infection and unplanned reoperation(s) within 3 months following the initial surgery. Results: In total, 72 patients were treated for GBS-infected DFUs. Intra-operative culture of infected bone identified GBS in 16 patients (22.2%). Significantly more black patients (p=0.017) were afflicted by GBS DFUs. Patients with GBS DFUs had higher initial haemoglobin A1C levels (p=0.019), and those with tenosynovial involvement were likely to require reoperation (p=0.036) and had a greater total number of surgeries (p=0.015) than those without. Conclusion: GBS-infected DFUs are more common in black patients and those with elevated haemoglobin A1Cs. GBS infections with tenosynovial involvement are particularly destructive and require aggressive treatment by surgeons. Declaration of interest: The authors have no conflicts of interest.